Literature DB >> 29469716

Associated conditions in patients with multiple dermatofibromas: Case reports and literature review.

Surget V Beatrous1, Ryan R Riahi, Stratton B Grisoli, Philip R Cohen.   

Abstract

Dermatofibromas are benign, fibrohistiocytic, dermal tumors. Solitary dermatofibromas may be incidental findings, whereas multiple dermatofibromas may be associated with systemic conditions or previous therapies. Two women and one man with multiple dermatofibromas and an associated systemic condition, immunosuppression, or both, are described. Nine dermatofibromas developed in a woman with hypothyroidism, optic neuritis, and Arnold Chiari I malformation. Five dermatofibromas developed in a woman with breast cancer who had received several systemic antineoplastic therapies. Eleven dermatofibromas developed in a man with HIV whose systemic therapies included acyclovir, darunavir/cobicistat, dolutegravir, etravirine, and ritonavir. Conditions associated with multiple dermatofibromas include autoimmune diseases, cancer, chromosomal abnormalities, immunodeficiencies, metabolic disturbances, and altered physiologic states such as pregnancy. Medications received by patients with multiple dermatofibromas included immunosuppressive agents, psoriasis therapies, and antineoplastic drugs. Multiple dermatofibromas can be observed in patients with associated medical conditions, systemic therapies, or both. Therefore, in individuals presenting with multiple dermatofibromas, not only evaluation for associated disorders, but also review of prior and current drug therapies, should be considered.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29469716

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  2 in total

1.  Postherpetic Pruritus: A Potential Complication of Herpes Zoster Virus Infection.

Authors:  Shahzeb Hassan; Philip R Cohen
Journal:  Cureus       Date:  2019-09-16

2.  Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia.

Authors:  Francisco J Lira-Valero; Liliana Godínez-Aldrete; Nancy Pulido-Díaz; Marissa J Quintal-Ramírez
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.